Providence Health & Services - Oregon

Providence Health & Services - Oregon, doing business as Providence VNA Home Health, is a non-profit hospital system and subsidiary of Providence ST Joseph Health that operates as a prime recipient of federal research grants (40% of recent awards) and as a sub-recipient on clinical research programs (60%), with a primary federal footprint in cancer immunotherapy and health services research funded by the National Institutes of Health. The organization's headquarters are in Renton, Washington, with place of performance centered in Portland, Oregon.

Providence Health & Services - Oregon competes without set-aside designations across full-and-open federal grants. Recent prime awards from the National Cancer Institute span investigator-initiated research into tumor microenvironment remodeling in head and neck and colorectal cancer, immunoradiotherapy combination therapies, and radiologic imaging development. A $1.431 million NIH R01 Project Grant (CFDA 93.395) awarded May 1, 2026, funds spatiotemporal molecular analysis of radiation-induced tumor microenvironment remodeling in head and neck cancer through April 30, 2031, with clinical-trial and immunophenotyping work performed at Providence Portland Medical Center. A $437,113 NIH R21 Project Grant awarded June 8, 2026, investigates the origin and plasticity of tumor-reactive regulatory T cells in mismatch-repair proficient colon cancer using single-cell RNA and T cell receptor sequencing, running through May 31, 2028. A $347,374 USDA Rural Utilities Service Distance Learning and Telemedicine Grant (CFDA 10.855) awarded August 7, 2023, supported telehealth and remote medical education delivery to rural Oregon populations through August 2025. Completed work includes an NIH-funded study of dendritic cell gene regulation in anti-tumor immunity (January 2023–December 2024) and soft tissue sarcoma development mechanisms (September 2022–August 2025).

Customer concentration centers on the National Institutes of Health and its component institutes. The National Cancer Institute anchors 10 awards with investigator-initiated R01 and R21 mechanisms; the National Institute on Aging funds 2 awards in dementia care navigation and ALS natural history; and the Food and Drug Administration carries 5 awards. The Department of the Army Corps of Engineers holds 4 awards with $216 thousand combined potential value. The USDA Rural Utilities Service carries 1 award. Collectively, these five agencies account for 63% of recent award volume. Providence's sub-recipient portfolio reflects clinical research partnerships with University of California San Diego (multiple head and neck cancer immunoradiotherapy trials as Co-Principal Investigator site), University of California San Francisco (dementia caregiver support research), University of Minnesota (ALS natural history data collection), and Oregon Health & Science University (rural hospital improvement grants). Physical security and facility enhancement sub-awards funded improvements at Providence Newberg Medical Center, Providence Hood River Memorial Hospital, Providence Seaside Hospital, and Providence Medford Medical Center.

Prime and sub awards combined carry a potential value of $216 thousand on current federal grants, with $16.1 million in obligated dollars across the portfolio, indicating substantial invoiced revenue relative to remaining contract ceiling. Two awards reach ultimate completion within the next twenty-four months, creating modest near-term recompete exposure. The organization operates under a single Blanket Purchase Agreement (W9127N21A0002) with 2 task orders. Activity has been volatile, with 11 awards in 2023, declining to 8 in 2024, 4 in 2025, and 3 in 2026, suggesting either a slowdown in grant success or a shift in funding mechanism. Across the portfolio, Providence's capability posture centers on clinical research infrastructure for cancer immunotherapy and health services research, with operational emphasis on rural telehealth delivery and hospital facility management. The organization functions primarily as a research site and clinical-trial sponsor rather than as a federal service contractor or systems integrator.